Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
BörsenkürzelOBIO
Name des UnternehmensOrchestra Biomed Holdings Inc
IPO-datumAug 04, 2020
CEOHochman (David P)
Anzahl der mitarbeiter70
WertpapierartOrdinary Share
GeschäftsjahresendeAug 04
Addresse150 Union Square Drive
StadtNEW HOPE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl18938
Telefon16463439298
Website
BörsenkürzelOBIO
IPO-datumAug 04, 2020
CEOHochman (David P)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten